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Background: Osteoarthritis (OA) is a frustrating disease for both patient and 
physician because neither cause nor cure is known and there are currently 
no disease-modifying drugs. Objective: To review current therapeutic 
approaches as well as new findings regarding OA pathoetiology that could 
form the basis of future direction for the development of drugs to prevent 
or slow down disease progression. Methods: After reviewing disease 
progression in human OA, as demonstrated by histological analyses, the 
reasons for cartilage erosion are explored and possible therapeutic 
approaches are highlighted. Results/conclusions: OA may be an epigenetic 
disease. This new concept can explain many aspects of the disease and 
provide reasons why therapeutic approaches until now have met with 
little success.
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1.	 Introduction
Osteoarthritis (OA) is a degenerative condition that is caused by erosion of 
articular cartilage at diarthrodial joints  [1-3]. As a result cartilage can no longer 
fulfill its role as shock absorber. It is one of the most common disabling condi-
tions of elderly people in the Western world. As people reach retirement age, 60% 
of men and 70% of women will suffer from OA to some extent  [4]. Although the 
disease does not cause death, it severely affects the quality of life by making 
movement difficult and painful and significantly limiting everyday activities. 
As life expectancy increases, the number of people seeking relief from the pain 
and lack of mobility due to OA will increase every year. Joint replacements, so far 
the only ‘cure’ for arthritis, have met with enormous success and have trans-
formed the lives of millions of people. But they constitute drastic surgical 
intervention and, on average, last only 15 years, when revisions may become 
necessary. Therefore, a non-surgical treatment that either prevents OA or signi-
ficantly slows progression would be of enormous benefit. Current treatment 
regimes (paracetemol, NSAIDs, Cox-2 inhibitors, viscosupplementation with 
hyaluronans  [5,6]) can do no more than ameliorate the symptoms, such as pain 
and inflammation, but do not prevent the underlying tissue catabolism, so the 
disease still progresses. The holy grail of future drug development for OA would 
be disease-modifying drugs  [7,8], analogous to the disease-modifying antirheumatic 
drugs in the treatment of rheumatoid arthritis  [9,10].
2.	 Pathoetiology	of	OA
Any search for disease-modifying drugs for OA must start with a thorough 
understanding of the changes that characterize the disease process in humans. 
Animal models of OA have been useful but do not replicate several features 
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of the human disease, such as the decade-long progression 
or the formation of clusters of abnormal chondrocytes 
(see Section 2.5).
2.1	 Changes	in	the	cartilage	matrix	in	OA
As already mentioned, the key feature of OA is the loss of 
shock-absorbing capacity of articular cartilage, a result of the 
destruction of the extracellular matrix (ECM). Other joint 
tissues, that is, the synovial capsule, the ligaments, and the 
subchondral bone, are also affected, but it is the erosion of 
cartilage that causes the loss of mobility and pain. To under-
stand why cartilage erosion has such a devastating effect 
means understanding the function of the components of the 
ECM. Cartilage is a highly hydrated gel in which a small 
number (< 3%) of chondrocytes are embedded. Approximately 
70 – 80% of the wet weight of cartilage is water  [11], which is 
bound to the highly negatively charged aggrecan molecules 
that in turn swell. The amount it swells depends on the 
collagen network, which is comprised of type II collagen 
along with collagen types IX and XI. The latter provide 
tensile strength and compressive stiffness, whereas aggrecan 
and water provide elasticity. Other minor collagens, types 
III, VI, XII and XIV, also play a role in the cartilage matrix, 
as do other collagen-binding small proteoglycans, such as 
decorin, fibromodulin, lumican and perlecan, along with 
cartilage oligomeric matrix protein (COMP). Mutations in 
their genes give rise to defective cartilage and to early-onset 
OA  [12]. This illustrates the functional importance of even 
minor components of the cartilage matrix. However, most 
OA patients have no demonstrable defects in structural 
proteins. Therefore, the cause of their arthritis does not 
seem to involve alterations in ECM molecules.
2.2	 Histological	grading	of	OA	severity
The availability of human cartilage samples following joint 
replacement operations (with appropriate ethical permission) 
as well as new histological techniques and antibodies have 
enabled researchers not only to map the various stages of 
cartilage erosion quite precisely but also to relate the cellular 
changes associated with OA to the stage of cartilage erosion. 
The femoral head is particularly useful for such studies, as 
patients with osteoporosis (OP) frequently fracture (#) the 
neck of the femur (#NOF). The fracture is typically treated 
by hemi-arthroplasty so that the femoral head is available 
for research. It has long been known that there is an inverse 
relationship between OP and OA  [13]. Indeed, femoral heads 
from OP patients typically have healthy cartilage, which 
therefore constitutes an easily accessible control with which 
to compare OA cartilage.
The first understanding of the cellular changes involved 
in OA was based on histological observations of post-mortem 
cartilage. Mankin et al.  [14] developed a numerical scale, from 
0 (normal cartilage) to 14 (severe degradation), that graded 
the loss of structural organization, cellular characteristics, 
loss of Safranin O staining and tidemark integrity. 
More recently, a new grading system has been proposed by 
the Osteoarthritis Research Society International (OARSI)  [15], 
which divides the stages of degradation into six grades, with 
grades 1 – 4 representing cartilage changes and grades 5 – 6 
including changes in subchondral bone. Both systems are 
based on the histological appearance of the cartilage at a 
particular site, rather than on a patient-based score for 
overall OA severity. The same patient may have OA cartilage 
with a high score in the weight-bearing region and almost 
normal cartilage in non-weight-bearing regions.
With today’s techniques, we can go beyond documenting 
cartilage erosion. Immunocytochemistry allows defining the 
proteins produced by chondrocytes at specific stages in 
specific regions and, by incorporating fluorescent markers, 
metabolically active or apoptotic cells can be identified.
2.3	 Matrix	and	cellular	changes	start	at	the		
superficial	zone
Changes in the composition and subsequent loss of matrix 
always start at the surface – a fact difficult to reconcile with 
the hypothesis  [16] that changes in subchondral bone precede 
cartilage changes. Proteoglycans are lost before cartilage 
collagen, because loss of Safranin O staining in the superficial 
zones (Figure 1A – D) occurs whereas the cartilage collagen 
remains, as seen by the Sirius red stain (Figure 1E, F). In 
healthy cartilage matrix, the presence of proteoglycans masks 
the Sirius red binding sites, hence only that region from 
which proteoglycans have been lost shows the bright Sirius 
red stain of fibrillar collagen. Comparing the cartilage from 
#NOF patients with that of OA patients shows interesting 
similarities, as well as crucial differences. As expected, 
hardly any proteoglycan loss has occurred in the cartilage 
from non-weight-bearing regions of most #NOF patients 
(Figure 1A, E), but in weight-bearing regions the whole 
cartilage is thinner and proteoglycans are absent from the 
upper third of the tissue (Figure 1B, F). In fact, the histo-
logical appearance of this cartilage is remarkably similar 
to that from OA patients in non-weight bearing regions 
(Figure 1C, G). The crucial difference is that this is the 
worst-scoring cartilage of a #NOF patient, whereas it may be 
the best-scoring cartilage of an OA patient, whose cartilage 
at the weight-bearing region will have been eroded right 
down to the subchondral bone. This suggests that the early 
stages of cartilage loss occur in both osteoporotic and 
osteoarthritic patients but do not reach clinical significance 
in OP patients, either because the process started at a later 
age or because the early changes have not progressed. 
One important but often not appreciated conclusion is that 
differences in cartilage erosion in OA and OP may be in 
degree rather than in kind.
2.4	 Articular	chondrocytes	in	OA	undergo	a	change	
in	phenotype
Normal articular chondrocytes have a long life, low 
metabolic activity, divide rarely and slowly turn over the 
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cartilage matrix. The half-life of cartilage collagens has been 
estimated to exceed 100 years  [17], whereas aggrecan compo-
nents turn over in 3 – 24 years  [18]. Normal adult articular 
chondrocytes synthesize cartilage matrix proteins, such as 
collagen types II, IX and XI, the components of aggrecan 
and COMP. Normal articular chondrocytes do not produce 
enzymes such as matrix metalloproteases (MMPs), ADAMTSs 
or inflammatory cytokines. Yet all these proteases and 
cytokines plus many more abnormal gene products are 
expressed by some, but not all, chondrocytes of OA patients. 
The location of cartilage cells that express abnormal genes, 
the so-called ‘degradative’ chondrocytes  [19], follows the 
pattern of proteoglycan loss, starting at the surface of 
weight-bearing regions.
Chondrocytes in non-weight-bearing regions of the 
same patient, on the other hand, still resemble normal 
cartilage cells. This heterogeneity is usually overlooked in 
gene expression studies. There all chondrocytes from 
an OA patient are pooled, so as to obtain enough cells 
for RNA extraction. As a result, the abnormal gene 
expression of degradative chondrocytes will be confounded 
by still-normal chondrocytes.
2.5	 Abnormal	chondrocytes	increase	with		
disease	progression
Degradative chondrocytes increase in number and location 
as the disease progresses (Figure 2). Moreover, when a 
chondrocyte expresses one abnormal gene, it also seems to 
express other abnormal genes. This suggests that an overall 
permanent switch in the phenotype of the chondrocytes has 
occurred rather than short-term upregulation of one or more 
factors. Another feature is that the degradative chondrocytes 
have high metabolic activity, as visualized by Celltracker 
green fluorescence (Figure 2D, F). In contrast to healthy 
Figure	1.	Cartilage	erosion	with	 increasing	OA	grade.	A	– D, Safranin O staining illustrates the loss of proteoglycans from the 
superficial zone. E	– H, positive Sirius red stain of the cartilage collagen is only apparent in the region from which proteoglycans have 
been lost. In fracture of the neck of femur (#NOF) patients, healthy cartilage is present in non-weight-bearing regions (A, E), whereas 
loss of proteoglycans and some matrix fibrillations are apparent in weight-bearing regions (B, F). The latter is similar to early-grade OA 
cartilage (C, D). In high-grade OA cartilage, some cartilage has been eroded and the fibrillations and the regions of proteoglycan loss 
are more extensive (D, H). A, E from a 84-year-old female; B, F from a 85-year-old female; C, G from a 61-year-old male; D, H from a 
73-year-old female.
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articular chondrocytes, degradative chondrocytes undergo 
cell division, as evidenced by the frequent presence of 
doublets and quadruplets in low-grade OA (Figure 2C, D) 
and the typical clusters of 16 – 32 cells in high-grade OA 
(Figure 2F – J). The abnormal expression of proteases and 
other genes is inherited by all daughter cells so that all cells 
of a cluster are of the degradative abnormal phenotype.
The important characteristics of disease progression of 
human OA may be summarized as follows:
1. Chondrocytes change phenotype to ‘degradative’ 
chondrocytes, which express matrix-degrading enzymes as 
well as many other gene products that are not normally 
expressed by articular chondrocytes.
2. These ‘degradative’ chondrocytes are first found in 
the superficial zone, then co-localize with the region of 
aggrecan loss.
3. Degradative but not normal chondrocytes proliferate 
to form clones. Up to 64 cells have been observed 
in one clone. Because all cells within a clone produce 
the degradative enzymes, it seems reasonable to infer 
the abnormal gene expression pattern is transmitted to 
daughter cells.
4. With increasing severity of OA, degradative chondrocytes 
increase in number, first, as a result of cell division of 
the abnormal chondrocytes, and second, because 
cartilage cells in the intermediate and deep zones change 
phenotype to degradative chondrocytes.
3.	 Aggrecanases	and	MMPs	are	involved		
in	cartilage	erosion
Even before it was shown that some OA chondrocytes 
expressed matrix-degrading enzymes, biochemical studies 
had identified and characterized the enzymes involved 
in cartilage erosion. The first major group of 
enzymes to be identified were the MMPs, a family 
of over 23 secreted and cell surface-bound zinc- 
dependent endopeptidases that degrade numerous 
substrates at neutral pH  [20-22]. Of particular importance 
for degrading articular cartilage are collagenase-3 
(MMP-13), stromelysin (MMP-3) and the gelatinases 
MMP-2 and MMP-9, to name just a few. These enzymes 
are released in vivo as inactive pro-enzymes and require 
activation by fibrinolysin or active MMP-3. MMP 
production is generally accompanied by MMP inhibitors 
(TIMPs), but in OA the balance between them is altered 
so that there is an MMP excess over its inhibitors, resulting 
in matrix destruction  [22].
Figure	2.	Location	of	protease-expressing	‘degradative’	chondrocytes	in	low-grade	and	high-grade	osteoarthritis.	A	–	E, low 
grade OA (OARSI ∼ 1 – 2); F	–	J, high grade OA (OARSI ∼ 3); staining as indicated. Degradative chondrocytes are first apparent in the 
superficial zone as single cells or doublets (A) and their localization corresponds to the region of proteoglycan loss (B). The cells continue 
to divide (C) and daughter cells are highly metabolically active (D, F). In high-grade OA, the typical clones are apparent, in which all cells 
are immunopositive for all the enzymes examined. Enzyme activity is also present in the matrix (A, E, G, H, I), which is specially apparent 
after hyaluronidase treatment (E, I). C, J had not been pretreated with hyaluronidase.
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3.1	 Protease	inhibitors	as	targets	for	drug		
development
An obvious therapeutic approach is to increase natural 
enzyme inhibitors, restoring the normal balance 
between MMPs and inhibitors, or to develop new 
inhibitors with the aim of preventing cartilage destruction. 
Several synthetic oral inhibitors of MMPs have been 
developed. They are effective in vitro and in animal 
models of OA  [23,24]. However, trials in humans have 
been disappointing, either because of adverse side 
effects, such as musculoskeletal pain and tendonitis, or 
because the drugs lacked efficacy. Inasmuch as MMPs 
also play a role in many other physiological processes  [25,26], 
the incidence of adverse effects resulting from general use 
is not surprising.
The lack of efficacy has been attributed to the fact 
that the drugs administered orally might not diffuse 
to the joint in adequate amounts and/or not penetrate 
into the cartilage. Alternatively, the synthetic inhibitors 
may not inhibit all relevant MMPs and non-inhibited 
enzymes could conceivably compensate for the absence 
of the inhibited MMPs  [21]. Moreover, the first stage 
in cartilage erosion is loss of aggrecan, not collagen, 
with aggrecanase activity preceding that of MMPs. 
As long as aggrecan is present in the cartilage matrix, 
collagen is protected from degradation even when 
activated MMPs are present  [27]. Aggrecanase-1 and -2 
(ADAMTS-4 and -5) are the main enzymes involved in 
aggrecan degradation  [28]. ADAMTS-5 appears to be the 
most important aggrecanase in mice, as targeted deletion 
of ADAMTS-5 but not of ADAMTS-4 prevents the 
development of OA following meniscal destabilization  [29-31]. 
However, in humans, both aggrecanases play a role  [32]. 
Theoretically, if ADAMTS-4 and -5 rather than the MMPs 
were targeted, initial cartilage loss would be prevented.
An alternative explanation for the lack of efficacy 
is that degradative chondrocytes themselves are a major 
source of the degradative enzymes as the disease 
progresses. In order to neutralize the degradative enzymes 
from the chondrocytes, the inhibitors would have to 
diffuse into the cartilage matrix. The amount of diffusing 
inhibitor may be insufficient in the light of the 
continually produced enzymes by an increasing number 
of chondrocytes. A far more productive strategy for thera-
peutic treatment would appear to be to prevent 
abnormal protease expression by chondrocytes. But this 
requires understanding what regulates expression of the 
degradative proteases.
4.	 Inflammatory	cytokines	as	targets	for		
drug	development
Inflammatory cytokines such as IL-1β, TNF-α and 
oncostatin M (OSM)  [33,34] are known to induce expression 
of the degradative enzymes  [35-39]. In addition, other 
inflammatory mediators such as nitric oxide  [40-42], reactive 
oxygen species  [43-45] and prostaglandin E2  [46,47] also 
contribute to cartilage destruction. It is IL-1β and/or 
TNF-α, however, which, perhaps in synergy with OSM, 
seem to play a central role in OA pathology.
When addition of IL-1β and/or TNF-α to monolayer 
cultures of chondrocyte cell lines was found to induce 
expression of degradative enzymes, an explosion of studies 
utilized these experimental models to describe signal trans-
duction and other regulatory pathways. Yet how relevant are 
these cell cultures to human OA? IL-1β is an important 
catabolic cytokine in rheumatoid arthritis  [48] and the four 
IL-1β signaling cascades are functional in both normal and 
OA chondrocytes  [49]. However, IL-1β is not significantly 
upregulated in OA chondrocytes. Moreover, OA is not a 
classical inflammatory arthropathy. Nevertheless, synovial 
inflammation is common in both early and late stages  [50] 
and a relationship seems to exist between the levels of 
IL-1β and TNF-α in OA synovial fluids and the levels of 
catabolic enzymes and other inflammatory mediators such as 
prostaglandins and nitric oxide  [38,46,51]. OA chondrocytes, 
especially in the superficial zone and in clonal clusters, 
are positive for IL-1β immunostaining  [49,52,53]. IL-1β  
colocalizes with TNF-α, MMP-1, -3, -8, and -13, and with 
type II collagen cleavage epitopes in regions of matrix 
depletion found in OA cartilage  [53,54]. Adenoviral transfer 
of IL-1β with OSM induces significant joint damage in 
a murine model  [55]. It may be possible that the locally 
produced IL-1β is of importance in influencing chondrocyte 
responses in an autocrine–paracrine manner, rather than 
overall levels of the cytokine. This may become apparent 
only in selected chondrocytes. Its expression would therefore 
not be detectable when RNA is extracted from the entire 
OA cartilage.
4.1	 Signal	transduction	mechanisms	as	possible		
drug	targets?
If inflammatory cytokines are indeed important in the 
pathoetiology of human OA, what should be the 
targets of drug action? There are two possible approaches: 
the first depends on interfering with the signal 
transduction mechanisms of IL-1β/TNF-α with the aim 
of preventing trans-activation of the target genes; 
the second depends on preventing the expression of 
the abnormal cytokines and/or their target genes by 
preventing promoter activation. Il-1β, TNF-α and OSM 
have different membrane-based receptors (Figure 3), but 
their signal transduction cascades converge (Figure 3). 
Ultimately, this leads to binding of various trans cription 
factors to the promoter regions of target genes and to 
gene trans-activations  [2]. Details are beyond the scope 
of this review, but in principle it involves the MAPK 
family, which comprises extracellular signal-regulated 
protein kinases (ERKs), p38 kinase in its various isoforms 
and the C-Jun-N-terminal kinase (JNK)  [25]. The activities 
Potential	directions	for	drug	development	for	osteoarthritis
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of these kinases converge on several transcription factors, 
NF-κB in particular. The latter upregulates expression of the 
various MMPs and ADAMTSs, as well as of the inflamma-
tory cytokines  [56-58], but suppresses the synthesis of ECM 
proteins. Thus, NF-κB mediates the two major changes 
in gene expression in OA chondrocytes: suppression of 
normal chondrocyte gene products and induction of 
abnormal genes.
Available inhibitors for each of the JUN, ERK and 
p38 kinase isoforms are mostly used for research. They 
probably will not constitute effective treatment for OA, 
inasmuch as MAPK signaling pathways regulate many 
other physiological processes, including cell growth, differ-
entiation, and apoptotic cell death  [59]. Therefore, any one 
of these inhibitors, systemically applied, will almost certainly 
have adverse side effects.
5.	 Is	induction	of	abnormal	genes	due	to		
epigenetic	‘unsilencing’?
An alternative strategy to targeting signal transduction 
pathways would be to target the epigenetic mechanisms that 
induce the cell type specific gene expression pattern of 
somatic cells. In each cell type, only those genes are expressed 
that are appropriate to its phenotype, with all other genes 
silenced. How is this selectivity achieved and maintained? 
Could a defect in selectivity underlie the inappropriate 
expression of abnormal genes in OA? All somatic cells 
contain the full gene apparatus of a person, but only a 
fraction of the genes is expressed in a given phenotype. 
Gene expression is regulated by two basic mechanisms, 
depending on whether the gene is part of the repertoire 
of the particular cell type or whether the gene is 
Figure	3.	Signal	transduction	pathways	in	chondrocytes.
AKT: Protein kinase B; ATF-2: Activating transcription factor-1; DD: Death domain; ELF: E74-like factor; ERK: Extracellular signal-related kinase; ETS: E Twenty Six; 
Fos: v-Fos homolog osteosarcoma oncogene; gp 130: Glycoprotein 130; IκB: Inhibitor of kappa B; IL: Interleukin; IL-1RI: Type I IL-1 receptor; IL-1RAcP: IL-1 receptor 
accessory protein; IRAK: IL-1 receptor associated kinase; JAK: Janus activating kinase; JNK: c-Jun N-terminal kinase; MAPK: Mitogen-activated protein kinase; 
MEKK1: Mitogen-activated ERK kinase kinase; MKK: MAPK kinase; Myc: Myogenic transcription factor; MYD88: Myeloid differentiation primary response gene 88; 
NF-κB: Nuclear factor kappa B; OSM: Oncostatin M; P: Phosphate; PI3K: Phosphoinositol 3-kinase; RAF: Receptor associated factor; RIP: Receptor-interacting protein; 
Stat3: Signal transducer and activator of transcription; TIR: Toll/IL-1 receptor domain; TNF-α: Tumor necrosis factor alpha; TNF-R1: Tumor necrosis factor receptor 1; 
TRADD: TNF receptor-associated death domain receptor; TRAF2: TNF receptor associated factor 2.
Reprinted with permission from [2].
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permanently silenced. All those genes in the first 
category are regulated by specific transcription factors in 
combination with cofactors, for example, enhancers and 
repressors. All other (i.e., never-expressed) genes are 
permanently silenced by the epigenetic mechanisms outlined 
below. Many studies have examined the promoter 
regulation of specific genes of relevance in OA in order 
to understand both the down regulation of normal 
chondrocytic genes, such as COL2A1, and the activation 
of abnormal genes, such as the MMPs. If transcriptional 
activation of abnormal genes can be prevented, synthesis 
of the degradative proteases may also be prevented, as 
would cartilage erosion. MMP-13 is an example of a 
gene product that results from de novo activation 
in OA. Activation of the MMP-13 promoter depends 
on transcription factors Runx-2, NF-κB, members of 
the ETS family of transcription factors and AP-1  [60-62]. 
On the other hand, repression of COL2A1 involves 
repression of Sp1 by Sp3  [63], EGR-1  [64] and ESE-1  [65].
Most studies of promoter regulation have used PCR- 
generated promoter constructs. Although very useful for 
analyzing transcription factors, the studies do not take 
account of the epigenetic mechanisms that, in vivo, can 
override transcriptional activation and thus cause genes 
to be silenced.
To illustrate the differences between epigenetic and 
transcriptional control of gene expression, a useful analogy is 
the process involved in entering a room through a door. 
If the door is locked, depressing the door handle will not 
open the door and entry is prevented. This is analogous to 
the permanent silencing of a gene that cannot be activated, 
even when the right transcription factors are present. 
However, unlocking the door is also not sufficient to permit 
entry. Rather the door handle must still be depressed after 
unlocking in order to open the door. This is analogous to 
binding of the required transcription factors to the promoter 
region. PCR-generated promoter constructs are analogous to 
a door that has been unlocked so that only the relevant 
transcription factors are required.
5.1	 Epigenetic	silencing	of	genes
Epigenetics is defined as heritable changes in gene function 
that cannot be explained by changes in DNA sequence. 
Epigenetic information is encoded by DNA methylation, 
histone modifications and changes in chromatin compaction. 
Conformationally relaxed chromatin (euchromatin) indicates 
transcriptionally active regions and is associated with a low 
level of DNA methylation, acetylation of histones-3 and -4, 
as well as methylation of histone-3 at lysine-4. Compact 
chromatin (heterochromatin) is transcriptionally silent, has a 
high degree of DNA methylation, and is bound to non-
acetylated histones with methylation at histone-3, lysine-9 
and -27  [66]. In the course of development, the extensive 
reprogramming of gene expression by epigenetic gene-control 
mechanisms takes place to obtain appropriate tissue-specific 
gene-expression patterns  [67]. Epigenetics also lies at the heart 
of phenotypic variations in health and disease, so targeting the 
epigenome holds great promise for preventing and treating 
complex human diseases  [68].
DNA methylation is the major heritable component of 
epigenetics. DNA is methylated when methyl groups are 
added to 5′-cytosines next to guanines (CpG sites) by DNA 
methyltransferases (Dnmts)  [69,70]. Dnmt3a and Dnmt3b 
cause de novo methylation of primarily unmethylated DNA 
and play a major role in establishing the DNA methylation 
pattern during development. Dnmt1 is responsible for 
maintaining established methylation patterns during cell 
division. Methylated CpG sites attract methyl-binding 
proteins, which recruit a variety of co-repressors, such as 
histone deacetylases  [71-73], histone methyl transferases 
and heterochromatin coating factors like HP1  [73,74]. 
The methyl- binding proteins thus act as a bridge 
between DNA methylation and histone modifications  [75,76]. 
Histone methylation at histone 3-lysine 9 may also 
induce DNA methylation  [74]. Gene silencing thus depends 
on both histone modification and DNA methylation, 
and is maintained in a manner specific for the cell 
type during mitosis, although the precise mechanisms 
are not well understood  [77]. Deviations from the 
DNA methylation pattern can result in either too much 
DNA methylation, which can lead to abnormal silencing 
of essential genes, or too little DNA methylation and the 
likelihood of abnormal expression of previously silenced 
genes  [78,79]. An important point is that the abnormal 
DNA methylation status is transmitted to daughter cells, 
because cells have no memory of their cell type specific 
epigenetic status. Moreover, unlike repair by DNA excision, 
no mechanisms are known that normalize altered DNA 
methylation patterns. This is why abnormal DNA methyla-
tion patterns can have such devastating effects. In the 
last 20 years, the study of epigenetics has expanded 
greatly and there is convincing evidence that the 
methylation status is altered in disease and that the 
alteration is maintained and passed onto daughter cells. 
Such changes have been reported for cancer  [80], for 
auto immune diseases  [81] and for the inflammatory 
rheumatic diseases, rheumatoid arthritis and lupus 
erythmatosus  [82-85]. Similar changes may also be involved 
in other complex diseases  [68,86,87].
5.2	 Do	epigenetic	changes	occur	in	OA?
Could altered DNA methylation play a role in OA? If so, 
one would predict DNA demethylation in the promoter 
regions of those genes that are expressed de novo in OA 
(e.g., the proteases) and high promoter methylation for 
those genes (e.g., cartilage collagens or aggrecan) that 
are silenced in OA chondrocytes. Of the few studies of 
epigenetic gene regulation in OA, the study that by 
Roach et al.  [19] was the first to investigate whether 
demethylation or ‘unsilencing’ could explain the abnormal 
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gene expression of four key proteases involved in OA, 
namely MMP-3, MMP-9, MMP-13 and ADAMTS-4. The 
promoters of all four proteases contain relatively few CpG 
sites, the so-called sparse CpG promoters  [19,88], in contrast 
to genes that contain many closely spaced CpG sites, 
the so-called CpG island promoters. Investigation of the 
DNA methylation status of CpG sites revealed that in 
chondrocytes from control (#NOF) patients most CpG sites 
were methylated  [19], consistent with the silencing of 
four proteases in these chondrocytes. However, significant 
loss of DNA methylation had occurred at specific CpG sites 
in the degradative chondrocytes of OA patients (cf. Table 1 
and  [19]). Another example is the abnormal expression of 
leptin in OA, which is also the result of an epigenetic loss 
of DNA methylation in OA chondrocytes  [89]. These 
two examples provide ‘proof of principle’ in as much as 
abnormal gene expression by ‘degradative’ OA chondrocytes 
in both conditions is associated with epigenetic loss of 
DNA methylation.
Poschl et al.  [90] have investigated whether the loss of 
aggrecan expression in OA was linked to high DNA methy-
lation of the promoter. Although the aggrecan promoter 
contains a CpG island, increased DNA methylation was 
ruled out as cause for silencing this cartilage-specific gene. 
Data from the Human Epigenome Project  [91] may provide 
an explanation. This Project studied the DNA methylation 
status of 1.8 million CpG sites in 873 genes located on 
chromosomes 6, 20 and 22 in 12 different tissues and 
showed that 88% of CpG island promoters are un-methylated, 
irrespective of expression, whereas at least 50% of sparse 
promoters are have a high level of DNA methylation in 
non-expressing cells. The findings of Poschl et al.  [90] suggest 
that the silencing of aggrecan in OA is not owing to 
hypermethylation of the CpG island but may involve 
other mechanisms, perhaps histone modification or repressor 
activation. The absence of hypermethylation in a gene 
silenced in OA thus contrasts with the well-documented 
silencing by hypermethylation in tumor suppressor genes  [92], 
where epigenetic therapy based on reversing the hyper-
methylation has been approved for the treatment of certain 
types of cancer  [80,93].
6.	 Expert	opinion:	Is	OA	an	epigenetic		
disease?
It is the author’s hypothesis that OA is a disease in 
which abnormal genes are activated, because of epigenetic 
unsilencing. These genes include the typical cartilage- 
degrading enzymes, that is, aggrecanases and MMPs, and 
also numerous other genes, including IL-1β. The epigenetic 
unsilencing is responsible for the phenotypic change 
from normal to ‘degradative’ chondrocytes. As yet, we do 
not know what induces unsilencing. Excess mechanical 
forces, joint instability or episodes of synovial inflammation 
(Figure 4) are possible initiating factors that affect 
chondrocytes in the superficial zone to set in motion 
the phenotypic changes to degradative chondrocytes. 
An important observation is that not all chondrocytes are 
affected simultaneously in OA, as would be the case 
if OA was predominantly a genetic disease. Rather the 
phenotypic changes start in a few cells in the superficial 
zone of the weight-bearing regions, then propagate over 
a period of 10 – 30 years to cells of the intermediate and 
deep zones and to non-weight-bearing regions (Figure 4). 
Epigenetic changes in progressively more chondrocytes may 
thus explain the progressive nature of OA. There is no 
doubt that genetic predisposition is important in OA  [94,95], 
but, in the author’s view, it is the epigenetic changes that 
actually lead to cartilage erosion in a particular patient.
Given the arthritogenic effects of IL-1β/TNF-α, 
it would be of interest to know whether these cytokines 
demethylate specific CpGs in the promoters of their 
target genes. There is evidence that demethylation 
(in combination with histone acetylation) is the mechanism 
by which IL-1β exerts its effects  [96]. The author’s group 
has preliminary evidence that IL-1β or TNF-α causes 
loss of DNA methylation at specific CpG sites in 
specific promoters in vitro. A model in which loss of 
DNA methylation can be induced is in current use to 
test whether substances that are known to protect 
chondrocytes from the arthritogenic effects of IL-1β, 
such as glucosamine  [97] or hyaluronan  [98], exert their 
effects by preventing demethylation. The system can also be 
Table	1.	Promoter	CpG	methylation	for	four	cartilage-degrading	enzymes	in	controls	(#NOF	patients)	and		
OA	patients.
MMP-3 MMP-9 MMP-13 ADAMTS-4 Overall	mean
#NOF 70 ± 7 53 ± 11 96 ± 2 100 80 ± 4
OA 41 ± 6 19 ± 5 80 ± 4 50 ± 6 51 ± 3
p-Value 0.007 0.015 0.012 < 0.001 < 0.001
DNA was extracted from the articular cartilage from the deep zone of #NOF patients, whose chondrocytes did not express the proteases, and from the surface zones 
and around the weight-bearing regions in OA patients, because only those regions contained protease-expressing ‘degradative’ chondrocytes. The numbers show 
the means (and SD) of the percentage of CpG sites that were methylated in 10 #NOF patients and 16 OA patients. These were derived from the data presented 
in  [17]. 
CpG: Cytosine-phosphate-guanine; #NOF: Fracture of the neck of femur; OA: Osteoarthritis.
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used to test other compounds and may therefore become 
a first screening test for epigenetic therapy.
To date most epigenetic therapy is based on preventing or 
reversing hypermethylation or chromatin compaction of 
tumor suppressor genes by applying non-specific DNA 
methyltransferase inhibitors (e.g., 5-aza-deoxycytidine) or 
histone deacetylase inhibitors (e.g., trichostatin A)  [99]. For 
OA, the opposite approach would be required, namely 
inhibiting the loss of DNA methylation in the promoters 
of proteases and/or cytokines would prevent or slow down 
cartilage erosion. A drug capable of achieving this would 
indeed be a disease-modifying drug. In addition, if the genes 
expressing the proteases and cytokines could be silenced by 
site-specific DNA methylation, this would constitute a cure 
for OA. Both strategies depend on defining the epigenetic 
differences between control and degradative OA chondrocytes, 
and on understanding the mechanism of DNA demethyla-
tion in articular chondrocytes. At present, the questions far 
exceed the answers. We need to study the mechanisms of 
DNA methylation loss, how histone modifications are 
involved, why only some CpGs in some genes are demethy-
lated, whereas in others the methylation status remains 
unchanged even when exposed to the same stimuli. In parti-
cular, we need to understand the specific nature of 
DNA methylation for a given cell type.
Preventing DNA demethylation might be effective in the 
early stages of the disease. A far more difficult undertaking 
would be to reinduce epigenetic gene silencing by epigenetic 
means in OA chondrocytes with already unsilenced genes. 
One way to accomplish this is to engineer zinc-finger 
proteins (ZFP) to bind to specific sequences on the DNA. 
In yeast cells, where no DNA methylation is present, 
a zinc-finger fused with the DNA methylase M.SssI has 
been shown to target methylation to CpG sites within 
353bp of the ZFP binding site  [100]. Greater specificity can 
be achieved by using several ZFP in combination. A con-
struct consisting of eight ZFP linked to the repressor domain 
KRAB, together with the corepressor KAP1, can effect the 
necessary co-ordination to bring about gene silencing at the 
site selected by the zinc fingers in NIH2T3 cells  [74], which 
includes DNA methylation. Engineered transcription 
factors, linked to an effector domain that functions to 
normalize disrupted DNA methylation status, are a 
promising tool to treat and possibly cure the defective DNA 
methylation that characterizes several diseases  [101]. Although 
remethylation at specific sites can be accomplished in 
yeast or cultured cells, but we do not know how to translate 
this to the human situation, because chondrocytes are 
present within lacunae, which are separated by large amounts 
of ECM.
Much time, expertise and funding are needed to reach the 
point when it is reasonable to proceed with the development 
of drugs for epigenetic therapy of OA. Yet, the holy grail of 
disease-modifying drugs for OA now seems to be within 
sight, a prospect that may benefit millions of elderly patients 
in the future.
Figure	4.	Epigenetic	changes	and	OA	progression. Inflammatory cytokines from the synovium cause normal articular chondrocytes 
(blue) in the superficial zone to change to ‘degradative’ OA chondrocytes (orange). This phenotypic change includes loss of DNA 
methylation in the promoters of many genes, which can result in aberrant gene expression, providing the required transcription factors 
are present. IL-1β (and other cytokines) are induced as part of the phenotypic change. Degradative chondrocytes proliferate and transmit 
the aberrant gene expression to daughter cells. IL-1β (and may be other cytokines) diffuse to adjacent, still healthy, chondrocytes and 
causes these to change phenotype to degradative cells, thus, propagating the abnormal phenotype.
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